Compare Bristol-Myers Squibb Co (BMY) vs YieldMax TSLA Option Income Strategy ETF (TSLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs YieldMax TSLA Option Income Strategy ETF — how do they compare? Bristol-Myers Squibb Co trades at $63.78 (market cap $129.94B), while YieldMax TSLA Option Income Strategy ETF trades at $21.61. The key difference: Bristol-Myers Squibb Co pays a 3.96% dividend while YieldMax TSLA Option Income Strategy ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, YieldMax TSLA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| BMY | TSLY | |
|---|---|---|
Market Cap | $129.94B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $65.89 | $48.25 |
52-Week Low | $42.60 | $20.49 |
Enterprise Value | $163.92B | — |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.83, down 1.56% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust fundamentals with a 14.01 P/E ratio, 18.87% net margin, and recent $2.3 billion manufacturing investment. Analyst consensus leans neutral with a $68.56 price target, while technical indicators suggest bullish momentum with key support at $63.
BMY presents a balanced opportunity with strong profitability and growth pipeline offset by patent expiration risks. The stock's current valuation appears reasonable with upside potential to analyst targets, though investors should monitor debt levels and competitive pressures in the pharmaceutical sector.
TSLY trades at $21.57, down 0.74% today, with a bearish technical outlook indicated by moving averages and key indicators. The ETF generates substantial income through weekly distributions, with recent dividends ranging from $0.23 to $0.52 per share. However, the structure caps upside potential during Tesla rallies, as noted in recent analyst commentary.
While TSLY offers high yield potential through its option income strategy, investors face significant risks including capped upside capture, volatility exposure from Tesla's underlying performance, and potential return of capital distributions. The neutral sentiment from oscillators suggests limited near-term directional momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About YieldMax TSLA Option Income Strategy ETF
TSLY is an actively managed ETF that seeks to provide high monthly income by employing a synthetic covered call strategy on Tesla, Inc. (TSLA). It does not own Tesla stock directly; instead, it uses a combination of call and put options to simulate long exposure while simultaneously selling call options to collect premiums. It is designed for income-focused investors who are willing to trade TSLA's potential upside for immediate, aggressive yield.
Read more on TSLY →
